[go: up one dir, main page]

IL258881B2 - FAECALIBACTERIUM PRAUSNITZII AND DESULFOVIBRIO PIGER FOR USE IN THE TREATMENT OR PREVENTION OF DIABETES AND INTESTINAL DISEASES - Google Patents

FAECALIBACTERIUM PRAUSNITZII AND DESULFOVIBRIO PIGER FOR USE IN THE TREATMENT OR PREVENTION OF DIABETES AND INTESTINAL DISEASES

Info

Publication number
IL258881B2
IL258881B2 IL258881A IL25888118A IL258881B2 IL 258881 B2 IL258881 B2 IL 258881B2 IL 258881 A IL258881 A IL 258881A IL 25888118 A IL25888118 A IL 25888118A IL 258881 B2 IL258881 B2 IL 258881B2
Authority
IL
Israel
Prior art keywords
strain
strains
faecalibacterium prausnitzii
butyrate
prausnitzii
Prior art date
Application number
IL258881A
Other languages
English (en)
Hebrew (he)
Other versions
IL258881A (en
IL258881B1 (en
Original Assignee
Metabogen Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabogen Ab filed Critical Metabogen Ab
Publication of IL258881A publication Critical patent/IL258881A/en
Publication of IL258881B1 publication Critical patent/IL258881B1/en
Publication of IL258881B2 publication Critical patent/IL258881B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
IL258881A 2015-10-28 2016-10-28 FAECALIBACTERIUM PRAUSNITZII AND DESULFOVIBRIO PIGER FOR USE IN THE TREATMENT OR PREVENTION OF DIABETES AND INTESTINAL DISEASES IL258881B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1519088.7A GB201519088D0 (en) 2015-10-28 2015-10-28 The use of bacteria formulations
PCT/EP2016/076038 WO2017072278A1 (en) 2015-10-28 2016-10-28 Faecalibacterium prausnitzii and desulfovibrio piger for use in the treatment or prevention of diabetes and bowel diseases

Publications (3)

Publication Number Publication Date
IL258881A IL258881A (en) 2018-06-28
IL258881B1 IL258881B1 (en) 2023-07-01
IL258881B2 true IL258881B2 (en) 2023-11-01

Family

ID=55130365

Family Applications (1)

Application Number Title Priority Date Filing Date
IL258881A IL258881B2 (en) 2015-10-28 2016-10-28 FAECALIBACTERIUM PRAUSNITZII AND DESULFOVIBRIO PIGER FOR USE IN THE TREATMENT OR PREVENTION OF DIABETES AND INTESTINAL DISEASES

Country Status (17)

Country Link
US (2) US11260082B2 (es)
EP (1) EP3368053A1 (es)
JP (1) JP7018396B2 (es)
KR (2) KR102371868B1 (es)
CN (2) CN115778986A (es)
AU (1) AU2016344770B2 (es)
BR (1) BR112018008312B1 (es)
CA (1) CA3002603A1 (es)
CL (1) CL2018001133A1 (es)
GB (1) GB201519088D0 (es)
IL (1) IL258881B2 (es)
MX (1) MX392357B (es)
RU (1) RU2754367C2 (es)
SG (1) SG11201803062XA (es)
UA (1) UA124926C2 (es)
WO (1) WO2017072278A1 (es)
ZA (1) ZA201802585B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11959125B2 (en) * 2016-09-15 2024-04-16 Sun Genomics, Inc. Universal method for extracting nucleic acid molecules from a diverse population of one or more types of microbes in a sample
TWI778083B (zh) * 2017-06-16 2022-09-21 日商表飛鳴製藥股份有限公司 脂肪關連疾患及/或炎症的預防或治療劑
JP2020530493A (ja) * 2017-08-07 2020-10-22 フィンチ セラピューティクス、インコーポレイテッド． 腸内の抗生物質耐性菌を除菌するための組成物及び方法
WO2019139943A1 (en) * 2018-01-09 2019-07-18 The Cleveland Clinic Foundation Treatment and prevention of pathogenic bacterial overgrowth using butyrate-producing bacteria
WO2020064764A1 (en) * 2018-09-25 2020-04-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of mam polypeptides for the treatment of obesity and obesity-related disorders
CN110878349A (zh) * 2019-12-06 2020-03-13 深圳谱元科技有限公司 终末期肾病生物标志物及其应用
EP3858363A1 (en) * 2020-01-28 2021-08-04 Institut national de recherche pour l'agriculture, l'alimentation et l'environnement Composition for treating intestinal or pulmonary diseases
NL2025020B1 (en) * 2020-02-28 2021-10-14 Acad Medisch Ct Intervention strategy for prevention or treatment of autoimmune diseases
EP4110328B1 (en) * 2020-02-28 2026-01-07 Stichting Amsterdam UMC Intervention strategy for prevention or treatment of diabetes mellitus, autoimmune disease, inflammatory disease or cardiovascular disease
KR102169794B1 (ko) * 2020-06-24 2020-10-27 주식회사 엔테로바이옴 신규한 피칼리박테리움 프로스니치 균주 eb-fpdk11 및 그의 용도
KR102169795B1 (ko) * 2020-06-24 2020-10-27 주식회사 엔테로바이옴 신규한 피칼리박테리움 프로스니치 eb-fpdk9 균주 및 그의 용도
KR102185828B1 (ko) * 2020-08-26 2020-12-03 주식회사 엔테로바이옴 피칼리박테리움 프로스니치 균주를 포함하는 아토피성 질환 예방 또는 치료용 약학적 조성물
KR102245415B1 (ko) * 2020-12-14 2021-04-29 주식회사 엔테로바이옴 피칼리박테리움 프로스니치 균주 배양 배지 조성물
US20240226030A1 (en) * 2021-05-06 2024-07-11 Société des Produits NESTLE S.A. Compositions and methods using at least one of inositol, erythritol or sorbitol to enhance growth of faecalibacterium prausnitzii
CN113201575A (zh) * 2021-05-11 2021-08-03 西安医学院第一附属医院 基于普氏粪杆菌对动物肾脏炎症反应变化影响的研究方法
CN113797232B (zh) * 2021-10-28 2023-05-26 南昌大学 具有缓解胰岛素抵抗功能的组合物及其应用
CN114304380A (zh) * 2022-01-13 2022-04-12 合肥河川生物医药科技有限公司 普拉梭菌在猪鸡上的应用
CN117384867B (zh) * 2022-09-16 2024-06-07 北京普译生物科技有限公司 一种经修饰的Cas3移位酶及其应用
CN117016672A (zh) * 2023-08-29 2023-11-10 天晴干细胞股份有限公司 一种诱导2型糖尿病饲料及其在建立2型糖尿病动物模型中的应用
CN118845848B (zh) * 2024-07-01 2025-10-17 温州大学 普氏粪杆菌dsm 17677在制备防治猪流行性腹泻病毒感染产品中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014137211A1 (en) * 2013-03-05 2014-09-12 Rijksuniversiteit Groningen Use of faecali bacterium prausnitzii htf-f (dsm 26943) to suppress inflammation.
WO2014152338A1 (en) * 2013-03-14 2014-09-25 Kabadi Mohan Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
US20150246081A1 (en) * 2014-03-03 2015-09-03 Shayne Kenneth Morris Probiotics with methods for growth and use separately and in combination

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) * 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
EP1861490A4 (en) * 2005-03-23 2010-11-17 Univ St Louis USE OF ARRAYS TO MODULATE NUTRIENT CAPTURE FUNCTIONS BY THE GASTROINTESTINAL MICROBIOTE
JP2007189947A (ja) * 2006-01-19 2007-08-02 Gifu Univ 硫化水素産生菌抑制剤及び硫化水素産生菌抑制方法
CN104159588A (zh) * 2011-11-04 2014-11-19 通用工厂公司 用于调节胃肠细菌以促进健康的方法和组合物
US9314494B2 (en) * 2012-05-25 2016-04-19 The United States Of America, As Represented By The Secretary Of Agriculture Cranberry xyloglucan oligosaccharide composition
US8906668B2 (en) * 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
EP2971027B1 (en) * 2013-03-15 2019-01-30 Amyris, Inc. Use of phosphoketolase and phosphotransacetylase for production of acetyl-coenzyme a derived compounds
CN111164706B (zh) * 2017-08-14 2024-01-16 普梭梅根公司 疾病相关的微生物组表征过程

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014137211A1 (en) * 2013-03-05 2014-09-12 Rijksuniversiteit Groningen Use of faecali bacterium prausnitzii htf-f (dsm 26943) to suppress inflammation.
WO2014152338A1 (en) * 2013-03-14 2014-09-25 Kabadi Mohan Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
US20150246081A1 (en) * 2014-03-03 2015-09-03 Shayne Kenneth Morris Probiotics with methods for growth and use separately and in combination

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HEINKEN, ALMUT, ET AL., FUNCTIONAL METABOLIC MAP OF FAECALIBACTERIUM PRAUSNITZII, A BENEFICIAL HUMAN GUT MICROBE., 30 September 2014 (2014-09-30) *
MARTIN R ET AL,, THE COMMENSAL BACTERIUM FAECALIBACTERIUM PRAUSNITZII IS PROTECTIVE IN DNBS-INDUCED CHRONIC MODERATE AND SEVERE COLITIS MODELS, 31 December 2014 (2014-12-31) *

Also Published As

Publication number Publication date
KR20210000758A (ko) 2021-01-05
KR102371868B1 (ko) 2022-03-07
BR112018008312A2 (pt) 2018-10-30
JP2018532779A (ja) 2018-11-08
US11260082B2 (en) 2022-03-01
AU2016344770B2 (en) 2023-07-13
RU2754367C2 (ru) 2021-09-01
HK1257739A1 (zh) 2019-10-25
AU2016344770A2 (en) 2018-05-17
IL258881A (en) 2018-06-28
BR112018008312B1 (pt) 2023-11-07
UA124926C2 (uk) 2021-12-15
WO2017072278A8 (en) 2017-12-07
MX392357B (es) 2025-03-24
ZA201802585B (en) 2019-07-31
EP3368053A1 (en) 2018-09-05
WO2017072278A1 (en) 2017-05-04
CN108367030A (zh) 2018-08-03
RU2021113597A (ru) 2021-06-25
MX2018005261A (es) 2019-07-04
AU2016344770A1 (en) 2018-05-10
IL258881B1 (en) 2023-07-01
CN115778986A (zh) 2023-03-14
CA3002603A1 (en) 2017-05-04
US12318412B2 (en) 2025-06-03
US20220133814A1 (en) 2022-05-05
GB201519088D0 (en) 2015-12-09
JP7018396B2 (ja) 2022-02-10
RU2021113597A3 (es) 2021-10-27
KR20180070698A (ko) 2018-06-26
RU2018119309A3 (es) 2020-03-26
SG11201803062XA (en) 2018-05-30
CL2018001133A1 (es) 2018-06-15
RU2018119309A (ru) 2019-11-28
US20200405777A1 (en) 2020-12-31
CN108367030B (zh) 2022-12-27

Similar Documents

Publication Publication Date Title
US12318412B2 (en) Faecalibacterium prausnitzii and Desulfovibrio piger for use in the treatment or prevention of diabetes and bowel diseases
Nieuwdorp et al. Role of the microbiome in energy regulation and metabolism
RU2642320C2 (ru) Пробиотические штаммы для лечения и/или профилактики диареи
US20210121505A1 (en) Compositions and methods for treating inflammatory bowel diseases
CN104918633A (zh) 一种微生物用于降低人体腔内三甲胺水平的应用,尤其是用于治疗三甲胺尿症或细菌性阴道炎以及预防心血管疾病
CN114728028A (zh) 包括具有增强的持久性的新微生物的组合物、新微生物和益生元的协同组合
WO2022236365A1 (en) Compositions and methods for treating disease
US20220249582A1 (en) Gaba-producing culturable bacteria and use for improving health
RU2797466C2 (ru) Faecalibacterium prausnitzii и desulfovibrio piger для применения при лечении или предупреждении диабета и заболеваний кишечника
HK40081859A (en) Faecalibacterium prausnitzii and desulfovibrio piger for use in the treatment or prevention of diabetes and bowel diseases
Hesser The Development of a Synbiotic Butyrate-Producing Bacterial Therapeutic for Food Allergy
HK1257739B (en) Faecalibacterium prausnitzii and desulfovibrio piger for use in the treatment or prevention of diabetes and bowel diseases
Cox The developmental role of the intestinal microbiota in shaping adult body composition